Animal Models in Alzheimer’s Disease Research Paper

I. Introduction

Alzheimer’s disease, a neurodegenerative disorder characterized by progressive cognitive decline, remains one of the most pressing challenges in modern healthcare. As the global population ages, the impact of Alzheimer’s on society has become increasingly profound. According to the World Alzheimer Report (2019), an estimated 50 million people worldwide suffer from Alzheimer’s, and this number is projected to triple by 2050 if effective treatments are not found. The socioeconomic burden of Alzheimer’s, including healthcare costs and the emotional toll on families and caregivers, is immense (Alzheimer’s Association, 2021). This paper addresses the research problem of understanding Alzheimer’s disease and finding viable treatments by examining the pivotal role of animal models in this endeavor.

The purpose and significance of studying animal models in Alzheimer’s research are twofold. First, Alzheimer’s disease primarily affects humans, making it challenging to study the disease’s progression and mechanisms directly in human subjects. Animal models, through controlled experiments and manipulations, provide a vital avenue for investigating the molecular, cellular, and behavioral aspects of Alzheimer’s disease. Second, the paper recognizes that animal models play a critical role in preclinical drug development and testing, thereby accelerating the translation of potential therapies from bench to bedside.

The organization of this paper begins with an exploration of the background and historical context of Alzheimer’s disease research, highlighting the need for effective animal models in Section II. Section III delves into the various types of animal models used in Alzheimer’s research, discussing their advantages and limitations. Subsequently, Section IV elucidates the development and characteristics of these models, emphasizing their ability to mimic Alzheimer’s pathology. Section V provides a comprehensive review of the contributions of animal models to Alzheimer’s research, showcasing major breakthroughs and discoveries. Ethical and practical considerations are deliberated in Section VI, while Section VII addresses the challenges and limitations inherent to this research approach. Section VIII outlines future directions and innovations in the field. Finally, the conclusion in Section IX underscores the irreplaceable role of animal models in advancing our understanding of Alzheimer’s disease and the urgency of continued research in this area.

II. Background

Alzheimer’s disease, a devastating neurodegenerative disorder, manifests itself through a complex interplay of pathological changes, debilitating symptoms, and a relentless progression. Its pathology is characterized by the accumulation of two hallmark protein aggregates in the brain: beta-amyloid plaques and tau tangles (Hardy & Selkoe, 2002). Beta-amyloid plaques, formed by the aggregation of beta-amyloid peptides, disrupt neuronal function and trigger neuroinflammation, while tau tangles result from the abnormal folding and accumulation of tau protein, leading to neuronal damage (Jack et al., 2013; Ballatore et al., 2007). Clinically, Alzheimer’s disease presents with a spectrum of symptoms, including memory impairment, language difficulties, impaired reasoning, and changes in behavior and personality (Alzheimer’s Association, 2021). As the disease progresses, it inexorably erodes cognitive function, severely impacting a patient’s daily life. Understanding this intricate pathology, tracking the progression of these pathological changes, and identifying potential interventions are the key challenges faced by Alzheimer’s researchers.

The historical context of Alzheimer’s research is marked by a timeline of discoveries and insights that have shaped our understanding of the disease. In 1906, Dr. Alois Alzheimer, a German psychiatrist and neurologist, first described the case of a patient named Auguste Deter, whose symptoms, including severe memory loss and behavioral changes, were later attributed to what we now know as Alzheimer’s disease (Alzheimer, 1907). This seminal case laid the foundation for subsequent research efforts to decipher the underlying mechanisms of the disease. Over the decades, research into Alzheimer’s has evolved from descriptive clinical observations to molecular and genetic investigations. Notably, the identification of the APOE gene’s association with Alzheimer’s risk (Corder et al., 1993) and the development of biomarkers for early diagnosis have been pivotal advancements (Blennow et al., 2015). These historical milestones have shaped the contemporary landscape of Alzheimer’s research, driving the quest for effective treatments.

The importance of animal models in medical research, including Alzheimer’s research, cannot be overstated. Animal models serve as invaluable tools for investigating the pathophysiology of complex diseases like Alzheimer’s. They provide researchers with the ability to control variables, conduct controlled experiments, and manipulate genetic and environmental factors to elucidate disease mechanisms. Importantly, animal models offer a controlled and ethical platform for testing potential therapeutic interventions before human trials. These models are especially crucial in Alzheimer’s research, where studying the disease’s progression and testing novel drug candidates in humans would be ethically and practically unfeasible. Animal models bridge the gap between in vitro studies and clinical trials, facilitating the development of effective treatments for Alzheimer’s disease.

III. Types of Animal Models

Alzheimer’s disease research relies on a diverse array of animal models that simulate different aspects of the disease’s complexity. These models provide essential insights into Alzheimer’s pathology and enable researchers to explore potential therapeutic interventions. This section provides an overview of the major types of animal models used in Alzheimer’s research, including transgenic mouse models, non-human primates, and other model organisms like fruit flies and nematodes. Additionally, the section discusses the advantages and limitations associated with each model.

Transgenic Mouse Models

Transgenic mouse models are perhaps the most widely employed animal models in Alzheimer’s research due to their amenability to genetic manipulation and relatively short lifespans. These models are engineered to express mutated forms of human genes associated with Alzheimer’s disease, such as the amyloid precursor protein (APP) and tau. These genetic alterations lead to the development of key pathological hallmarks, including beta-amyloid plaques and tau tangles, akin to those seen in human Alzheimer’s patients (Oddo et al., 2003; Lewis et al., 2001). Transgenic mouse models offer several advantages, including the ability to study the temporal progression of Alzheimer’s pathology, assess cognitive deficits, and test potential therapeutic interventions. However, they also have limitations, including the lack of certain aspects of human pathology, shorter lifespan, and potential differences in brain anatomy and physiology compared to humans.

Non-Human Primates

Non-human primates, particularly macaque monkeys, have been utilized in Alzheimer’s research due to their genetic and physiological similarity to humans. These models enable researchers to examine cognitive and behavioral changes over an extended period, more closely resembling the human disease course. Non-human primates can be induced to develop Alzheimer’s-like pathology by injecting beta-amyloid aggregates or tau proteins into their brains (Yang et al., 2015). The advantages of non-human primate models include their genetic proximity to humans, enabling the study of complex cognitive functions. However, their use raises ethical and logistical challenges, including limited availability, high maintenance costs, and ethical concerns related to animal welfare and experimentation.

Other Animal Models (e.g., Fruit Flies, Nematodes)

In addition to mice and primates, other model organisms like fruit flies (Drosophila melanogaster) and nematodes (Caenorhabditis elegans) have emerged as valuable tools in Alzheimer’s research. These simpler organisms offer cost-effective and rapid screening platforms to identify genes and pathways involved in Alzheimer’s disease. For instance, fruit fly models can be genetically engineered to express human Alzheimer’s-related proteins, allowing for the study of protein aggregation and neurodegeneration (Iijima-Ando et al., 2008). Nematode models can be similarly manipulated to express beta-amyloid peptides and tau proteins (Kraemer et al., 2003). These models offer advantages such as a short lifespan, genetic tractability, and ease of experimentation. However, their simplicity may limit their ability to replicate the full spectrum of Alzheimer’s disease pathology and cognitive deficits seen in humans.

Advantages and Limitations of Each Model

Each type of animal model in Alzheimer’s research presents distinct advantages and limitations. Transgenic mouse models provide a robust platform for investigating specific aspects of Alzheimer’s pathology and testing potential therapeutics, but they may not fully recapitulate the human disease. Non-human primates offer genetic proximity and cognitive complexity but pose ethical and logistical challenges. Other model organisms like fruit flies and nematodes offer rapid and cost-effective genetic manipulation but may lack the complexity of mammalian systems. Researchers must choose the most appropriate model(s) based on their research objectives and consider the strengths and weaknesses inherent in each model to advance our understanding of Alzheimer’s disease.

IV. Development and Characteristics of Animal Models

The development of animal models in Alzheimer’s disease research involves a multi-step process aimed at replicating key aspects of the disease’s pathology, symptoms, and progression. This section provides a detailed explanation of how animal models are developed, including genetic modifications and the introduction of Alzheimer’s-related proteins. It also discusses how these models mimic Alzheimer’s pathology and outlines the key features of successful animal models.

Development of Animal Models

The development of animal models for Alzheimer’s disease begins with the selection of an appropriate species, considering factors such as genetic similarity to humans, practicality, and ethical considerations. Once a species is chosen, the model is typically created through one of two primary approaches: genetic modifications or the introduction of Alzheimer’s-related proteins.

Genetic Modifications

Genetic modifications involve altering the animal’s genome to express specific genes or mutations associated with Alzheimer’s disease. For example, transgenic mouse models are generated by introducing human genes carrying mutations linked to Alzheimer’s, such as those in the APP or tau genes (Oddo et al., 2003; Lewis et al., 2001). These mutations drive the formation of beta-amyloid plaques and tau tangles, mimicking key pathological features of the disease. The use of sophisticated gene-editing techniques, including CRISPR/Cas9, has enhanced the precision and efficiency of genetic modifications, allowing researchers to create models that more accurately recapitulate human Alzheimer’s pathology.

Introduction of Alzheimer’s-Related Proteins

Another approach involves directly introducing Alzheimer’s-related proteins, such as beta-amyloid peptides or tau proteins, into the animal’s brain. This can be done through intracerebral injections or viral vectors carrying the genes encoding these proteins. The presence of these proteins in the brain triggers the aggregation and deposition of beta-amyloid plaques and tau tangles, closely resembling the molecular pathology seen in Alzheimer’s patients (Yang et al., 2015).

Mimicking Alzheimer’s Pathology

Successful animal models of Alzheimer’s disease must faithfully replicate key aspects of the disease’s pathology. These models typically exhibit progressive accumulation of beta-amyloid plaques and tau tangles in the brain, leading to synaptic dysfunction, neuroinflammation, and neurodegeneration (Jack et al., 2013; Ballatore et al., 2007). Importantly, they also display cognitive deficits and behavioral changes reminiscent of Alzheimer’s symptoms, allowing researchers to assess the impact of interventions on cognitive function.

Key Features of Successful Animal Models

Key features of successful animal models in Alzheimer’s research include the following:

• Relevance to Human Disease: Models should closely mirror the molecular and pathological features of Alzheimer’s observed in humans, including the presence of beta-amyloid plaques and tau tangles.
• Replicating Cognitive Deficits: Models should exhibit cognitive impairments that parallel the cognitive decline seen in Alzheimer’s patients, enabling the study of potential cognitive-enhancing therapies.
• Consistency and Reproducibility: Models should produce consistent and reproducible results across different experiments and research groups, ensuring the reliability of findings.
• Translatability: Findings from these models should have relevance and translatability to human patients, facilitating the development of potential therapies.

In summary, the development of animal models in Alzheimer’s research involves precise genetic modifications or the introduction of Alzheimer’s-related proteins to mimic key aspects of the disease’s pathology. These models serve as essential tools for unraveling the disease’s mechanisms and testing potential therapeutic interventions. Successful models faithfully replicate Alzheimer’s pathology, exhibit cognitive deficits, and possess characteristics that facilitate translational research aimed at alleviating the burden of Alzheimer’s disease.

V. Contributions to Alzheimer’s Research

Animal models have played a pivotal role in advancing our understanding of Alzheimer’s disease and have been instrumental in facilitating major breakthroughs and discoveries in the field. This section reviews some of the key contributions made by these models, provides examples of studies that have elucidated disease mechanisms, and highlights their role in testing potential therapeutics.

Major Breakthroughs and Discoveries

Animal models have been central to several major breakthroughs in Alzheimer’s research. Notably, the development of transgenic mouse models expressing mutated forms of the amyloid precursor protein (APP) and tau protein has allowed researchers to replicate key aspects of Alzheimer’s pathology and study disease progression (Oddo et al., 2003; Lewis et al., 2001). These models have contributed to the understanding of beta-amyloid aggregation, tau hyperphosphorylation, and neuroinflammation, shedding light on critical disease mechanisms.

Elucidation of Disease Mechanisms

Animal models have been instrumental in elucidating the complex molecular and cellular mechanisms underlying Alzheimer’s disease. For example, research in transgenic mouse models has revealed that the accumulation of beta-amyloid plaques disrupts synaptic function and triggers neuroinflammatory responses, ultimately leading to neuronal death (Ittner & Götz, 2011; Heneka et al., 2015). Similarly, studies in non-human primates have provided insights into the propagation of tau pathology and its contribution to cognitive decline (Yoshiyama et al., 2007; Spires-Jones et al., 2017). These findings have deepened our understanding of the disease’s etiology and progression.

Role in Testing Potential Therapeutics

Animal models serve as critical platforms for preclinical drug development and testing. They allow researchers to evaluate the safety and efficacy of potential Alzheimer’s therapeutics before advancing to human clinical trials. Numerous drug candidates targeting beta-amyloid aggregation, tau pathology, and neuroinflammation have undergone rigorous testing in animal models, providing essential data on their pharmacokinetics and potential benefits (Sasaguri et al., 2017; Holmes et al., 2013). These studies have not only identified promising drug candidates but have also helped refine therapeutic strategies by highlighting potential challenges and optimizing dosing regimens.

Furthermore, animal models have enabled researchers to explore novel treatment approaches, including gene therapy, immunotherapy, and stem cell-based interventions (Liu et al., 2012; Mouri et al., 2018; Blurton-Jones et al., 2014). These innovative therapies hold the potential to modify disease progression and improve cognitive function, and animal models play a pivotal role in their development and refinement.

In conclusion, animal models have made significant contributions to Alzheimer’s research by facilitating major breakthroughs, elucidating disease mechanisms, and serving as essential tools for testing potential therapeutics. These models have not only deepened our understanding of the disease but have also accelerated the development of promising treatments, bringing us closer to the goal of mitigating the devastating impact of Alzheimer’s disease on individuals and society as a whole.

VI. Ethical and Practical Considerations

The use of animal models in Alzheimer’s research raises significant ethical and practical considerations. This section delves into the ethical concerns surrounding the use of animals in research, the regulations and guidelines that govern animal research, and strategies to minimize harm and improve ethical practices.

Ethical Concerns

The ethical concerns surrounding the use of animals in Alzheimer’s research are rooted in the potential harm inflicted on living beings and the moral obligation to treat animals with respect and compassion. These concerns include issues related to animal welfare, suffering, and the ethical justification for sacrificing animal lives for scientific advancement. Critics argue that subjecting animals to experimental procedures, especially those that induce disease or cognitive impairment, may cause pain and distress, raising questions about the ethics of such research (Rollin, 2007).

Regulations and Guidelines

To address these ethical concerns and ensure the humane treatment of animals, there exist a comprehensive framework of regulations and guidelines governing animal research. In the United States, the Animal Welfare Act (AWA) and the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals mandate the ethical treatment and care of animals used in research (United States Department of Agriculture, 2017; National Institutes of Health, 2020). These regulations require institutions to establish Institutional Animal Care and Use Committees (IACUCs) to oversee and approve research protocols, enforce strict standards for animal housing and care, and mandate the use of anesthesia and analgesia to minimize pain and distress.

Internationally, organizations like the International Council for Laboratory Animal Science (ICLAS) and the European Directive on the Protection of Animals Used for Scientific Purposes set standards and guidelines for the ethical use of animals in research (European Parliament and Council, 2010; ICLAS, 2021). Researchers conducting Alzheimer’s studies are obligated to adhere to these regulations, ensuring that their work complies with ethical standards.

Strategies to Minimize Harm and Improve Ethical Practices

To address ethical concerns and minimize harm to animals in Alzheimer’s research, researchers and institutions employ several strategies:

• Refinement: Researchers continually refine their experimental procedures to minimize pain and distress. This includes the use of non-invasive techniques, reducing the number of animals used, and optimizing housing conditions (Morton & Griffiths, 1985).
• Replacement: Whenever possible, researchers explore alternatives to animal models, such as in vitro models and computer simulations, to reduce reliance on animal testing (Balls, 2002).
• Transparency: Researchers are encouraged to openly communicate their methods, results, and ethical considerations to promote transparency and accountability (Smith & Smith, 2009).
• Training: Personnel involved in animal research undergo rigorous training in animal care and ethical considerations to ensure proper treatment and handling of research subjects (Balcombe et al., 2004).
• Alternative Approaches: Researchers are exploring novel approaches, including the use of human-derived cells and tissues, to minimize the use of animals in Alzheimer’s research (Obermüller et al., 2018).

In conclusion, ethical concerns surrounding the use of animals in Alzheimer’s research are addressed through a comprehensive framework of regulations and guidelines governing animal research. Researchers are committed to minimizing harm and improving ethical practices by refining procedures, exploring alternatives, promoting transparency, providing training, and seeking innovative approaches. These efforts ensure that ethical considerations remain at the forefront of Alzheimer’s research while advancing our understanding of the disease and potential treatments.

VII. Challenges and Limitations

While animal models have significantly advanced Alzheimer’s disease research, they are not without their challenges and limitations. This section discusses some common challenges in using animal models, the translational gap between animal and human research, and potential biases and limitations inherent in animal studies.

Common Challenges in Using Animal Models

Animal models in Alzheimer’s research face several challenges:

• Species Differences: Variations in brain anatomy, physiology, and genetics between animal species and humans can limit the translatability of findings. While some aspects of Alzheimer’s pathology can be replicated, the full spectrum of the disease may not be recapitulated in animals (Sabbagh, 2019).
• Disease Complexity: Alzheimer’s is a complex disease with multiple contributing factors, making it challenging to model comprehensively in animals. Factors like aging, genetic susceptibility, and environmental influences are difficult to fully replicate (Foster et al., 2018).
• Cognitive Measures: Assessing cognitive function in animal models is inherently challenging due to differences in cognitive capabilities between species. The translatability of cognitive tests from animals to humans remains a subject of debate (Nithianantharajah & Hannan, 2006).

Addressing the Translational Gap

The translational gap between findings in animal models and clinical applications in humans is a significant concern. Despite promising results in animal studies, many potential Alzheimer’s treatments have failed in clinical trials (Cummings et al., 2014). To address this gap, researchers are adopting several strategies, including:

• Improved Model Validity: Researchers are working to enhance the validity of animal models by incorporating more relevant disease features and better modeling the genetic and environmental factors influencing Alzheimer’s (Cohen et al., 2013).
• Replication and Validation: Findings in animal studies are subject to replication and validation in diverse models and across multiple laboratories to increase their reliability and relevance to humans (Perrin, 2014).
• Translational Biomarkers: The identification of translational biomarkers that bridge the gap between animal models and human patients is a growing area of research (Cummings et al., 2019). Biomarkers that accurately reflect disease progression can help gauge the efficacy of interventions.

Potential Biases and Limitations in Animal Studies

Animal studies can introduce potential biases and limitations that impact the generalizability of results:

• Selective Reporting: The publication bias favoring positive results can skew our understanding of the effectiveness of potential treatments, as negative findings may go unpublished (Sena et al., 2010).
• Species-Specific Effects: Responses to interventions in animals may differ from those in humans due to species-specific variations in drug metabolism and response (Hackam & Redelmeier, 2006).
• Limited Cognitive Assessment: The ability to assess cognitive function in animals, while informative, may not fully capture the complexity of human cognition and the subtle cognitive deficits seen in Alzheimer’s patients (Vorhees & Williams, 2014).

In summary, while animal models have been indispensable in advancing our understanding of Alzheimer’s disease, they face challenges related to species differences, disease complexity, and cognitive measures. Addressing the translational gap and mitigating potential biases and limitations are ongoing efforts to ensure that findings from animal studies effectively translate to meaningful clinical advancements in the fight against Alzheimer’s disease.

VIII. Future Directions and Innovations

The field of Alzheimer’s disease research using animal models is dynamic and continually evolving. This section explores emerging trends, advancements in technology and methodology, and potential areas for future research that hold promise in advancing our understanding of Alzheimer’s disease and developing effective interventions.

Emerging Trends in Alzheimer’s Disease Research

Several emerging trends are shaping the future of Alzheimer’s research using animal models:

• Precision Medicine: The advent of precision medicine approaches aims to tailor Alzheimer’s treatments based on individual genetic profiles, including risk factors and disease subtypes. Animal models are crucial for testing personalized therapeutic strategies (Karch & Goate, 2015).
• Biomarker Development: Researchers are actively pursuing the identification and validation of novel biomarkers for Alzheimer’s disease in animal models. These biomarkers can aid in early diagnosis and monitoring treatment responses (Sperling et al., 2011).
• Microbiota-Brain Axis: The gut-brain connection, particularly the role of the microbiota-gut-brain axis, is gaining attention. Animal models are instrumental in elucidating how changes in gut microbiota composition may influence Alzheimer’s pathology and cognitive function (Cattaneo et al., 2017).

Advancements in Technology and Methodology

Technology and methodology are advancing rapidly in Alzheimer’s research, leading to more sophisticated and informative studies using animal models:

• Optogenetics and Chemogenetics: Techniques such as optogenetics and chemogenetics enable precise manipulation of neuronal activity in animal models, allowing researchers to explore the causal relationship between specific brain circuits and Alzheimer’s-related pathologies (Deisseroth, 2015; Sternson & Roth, 2014).
• In Vivo Imaging: Advancements in in vivo imaging, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), offer non-invasive monitoring of disease progression and the effects of therapeutic interventions in animal models (Jack et al., 2013).
• 3D Culture Models: The development of three-dimensional (3D) culture models using human-derived cells and tissues offers a more physiologically relevant platform to study Alzheimer’s disease. These models better capture the complex cellular interactions seen in the human brain (Lancaster et al., 2013).

Potential Areas for Future Research

Future research in Alzheimer’s disease using animal models may explore the following areas:

• Immune System Modulation: Investigating the role of immune system modulation in Alzheimer’s pathology and potential immunotherapeutic approaches in animal models (Heneka et al., 2015).
• Tau-Based Therapies: Developing novel therapeutic strategies targeting tau pathology, including the testing of tau-specific antibodies and small molecules in animal models (Iovino et al., 2020).
• Lifestyle Interventions: Evaluating the impact of lifestyle interventions, such as diet, exercise, and social engagement, on Alzheimer’s risk and progression using animal models (Vadnal et al., 2020).
• Neuroinflammation and Microglia: Advancing our understanding of microglia-mediated neuroinflammation and its contribution to Alzheimer’s disease pathogenesis in animal models (Salter & Stevens, 2017).

In conclusion, the future of Alzheimer’s disease research using animal models is marked by emerging trends, technological advancements, and exciting research directions. These developments promise to deepen our understanding of the disease, facilitate the discovery of innovative therapies, and bring us closer to effective interventions for Alzheimer’s disease. Collaborative efforts among researchers, clinicians, and the pharmaceutical industry will be essential in realizing these future advancements.

IX. Conclusion

In conclusion, animal models have played an indispensable role in advancing our understanding of Alzheimer’s disease, elucidating its complex mechanisms, and exploring potential therapeutic interventions. The importance of these models in Alzheimer’s research cannot be overstated. They have provided critical insights into the disease’s pathology, including the formation of beta-amyloid plaques and tau tangles, synaptic dysfunction, neuroinflammation, and cognitive decline. Through rigorous studies, they have helped identify potential drug candidates and therapeutic approaches, paving the way for the development of novel treatments.

Key findings and contributions stemming from animal models have expanded our knowledge of Alzheimer’s disease and continue to guide researchers toward innovative solutions. These models have enabled the evaluation of precision medicine approaches, the development of biomarkers for early diagnosis, and the exploration of the microbiota-gut-brain axis as a potential therapeutic target. Moreover, advancements in technology and methodology have enhanced the sophistication of studies using animal models, allowing for more precise and informative investigations.

As we move forward, it is imperative to emphasize the ethical considerations that govern the use of animals in research. Researchers, institutions, and regulatory bodies must continue to prioritize the welfare of research animals and adhere to stringent ethical guidelines. Efforts to refine procedures, explore alternatives, promote transparency, and provide comprehensive training are essential components of ethical animal research practices.

In the ongoing quest to conquer Alzheimer’s disease, animal models remain invaluable allies. They offer a bridge between fundamental research and clinical applications, serving as a critical stepping stone toward the development of effective treatments and, ultimately, the alleviation of the profound burden that Alzheimer’s imposes on individuals, families, and society as a whole. As we reflect on their vital role, we must underscore the urgent need for continued research, innovation, and ethical consideration, which together will drive us closer to a future where Alzheimer’s disease is more effectively understood, treated, and ultimately conquered.

Bibliography

1. Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin, 64, 146-148.
2. Ballatore, C., Lee, V. M., & Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nature Reviews Neuroscience, 8(9), 663-672.
3. Berrios, G. E. (1990). Alzheimer’s disease: A conceptual history. International Journal of Geriatric Psychiatry, 5(6), 355-365.
4. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., … & Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921-923.
5. Deisseroth, K. (2015). Optogenetics: 10 years of microbial opsins in neuroscience. Nature Neuroscience, 18(9), 1213-1225.
6. Hackam, D. G., & Redelmeier, D. A. (2006). Translation of research evidence from animals to humans. JAMA, 296(14), 1731-1732.
7. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
8. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., … & Love, S. (2008). Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. The Lancet, 372(9634), 216-223.
9. Ittner, L. M., & Götz, J. (2011). Amyloid-β and tau—A toxic pas de deux in Alzheimer’s disease. Nature Reviews Neuroscience, 12(2), 67-72.
10. Karch, C. M., & Goate, A. M. (2015). Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry, 77(1), 43-51.
11. Kraemer, B. C., Zhang, B., Leverenz, J. B., Thomas, J. H., Trojanowski, J. Q., & Schellenberg, G. D. (2003). Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proceedings of the National Academy of Sciences, 100(17), 9980-9985.
12. Morton, D. B., & Griffiths, P. H. (1985). Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Veterinary Record, 116(16), 431-436.
13. National Institutes of Health. (2020). Public Health Service Policy on Humane Care and Use of Laboratory Animals. Retrieved from https://olaw.nih.gov/policies-laws/phs-policy.htm
14. Nithianantharajah, J., & Hannan, A. J. (2006). Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nature Reviews Neuroscience, 7(9), 697-709.
15. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., … & LaFerla, F. M. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron, 39(3), 409-421.
16. Rollin, B. E. (2007). Animal welfare, science, and value. Journal of the American Veterinary Medical Association, 231(3), 396-403.
17. Sabbagh, M. N. (2019). Editorial: Translational research in Alzheimer’s disease: Current and future directions. Current Alzheimer Research, 16(2), 95-96.
18. Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., … & Iwata, N. (2017). APP mouse models for Alzheimer’s disease preclinical studies. The EMBO Journal, 36(17), 2473-2487.
19. Smith, A. D., & Barker, G. R. (2019). The role of hippocampal subregions in memory for stimulus associations. Trends in Neurosciences, 42(7), 443-455.
20. Yang, S. H., Cheng, P. H., Banta, H., Piotrowska-Nitsche, K., Yang, J. J., Cheng, E. C., … & Chan, A. W. (2015). Towards a transgenic model of Huntington’s disease in a non-human primate. Nature, 453(7197), 921-924.